Finnish Institute for Health and Welfare
Helsinki, 00271, Finland
NCT Number: NCT03273296
In recent years it has been observed that the gut microbiome can produce metabolites into systemic circulation and thus have important health effects even outside the gastrointestinal system. These metabolites may play a role in the pathogenesis of common public health problems such as diabetes, obesity and cardiovascular disorders. Modern techniques of mass spectrometry-based metabolomics from peripheral blood and gut metagenome sequencing now enable detailed examination of these processes. Using samples from the FINRISK 2002 cohort, collected by the National Institute for Health and Welfare, we are currently determining the gut microbiome and plasma metabolome from > 7000 participants with 15 years of follow-up for various health outcomes. This is one of the largest materials of its kind world-wide. The design does not, however, allow us to draw causal conclusions on the roles of gut bacteria in the composition of plasma metabolome. To enable conclusions which go beyond statistical associations, we now propose an extension to the FINRISK 2002 study, where we alter the gut bacteriome with a short course of antibiotics and then examine whether a change in plasma metabolomics profile will follow. At the same time the trial will give important novel information about the effects of commonly used antibiotics on gut bacteriome and on general health.
Looking for future studies?
Notify Me40 year–74 year
All sexes
Interventional
Phase 4
Helsinki, 00271, Finland
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Amoxicillin (po) 500 mg x 3 per day for 3 days.
Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
Vancomycin (po) 125 mg x 4 per day for 3 days.
Time frame: Baseline: 0 days; repeat assessments 2 days and 28 days after end of antibiotics.
Change in gut microbiome from baseline to repeat assessments.
Time frame: Baseline: 0 days; repeat assessments 2 days and 28 days after end of antibiotics.
Change in circulating metabolome from baseline to repeat assessments.
Finnish Institute for Health and Welfare
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05765422
Communicable Diseases, Disease Attributes
Nice, France
View Trial DetailsNCT07092046
Anesthesia Circuit, Anesthesia Equipment Bacterial Contamination
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07045636
Communicable Diseases, Digestive System Diseases
Guarulhos, São Paulo, Brazil
View Trial DetailsNCT05065671
Communicable Diseases, Disease Attributes
Somerville, New Jersey, United States
View Trial Details